Sodium valproate in Huntington's disease

Area of Science:

• Neuroscience
• Pharmacology
• Neurology

Background:

• Huntington's disease is a neurodegenerative disorder characterized by involuntary movements.
• Sodium valproate is known to increase gamma-aminobutyric acid (GABA) levels in the brain.
• GABAergic dysfunction is implicated in the motor symptoms of Huntington's disease.

Purpose of the Study:

• To evaluate the efficacy of sodium valproate in treating involuntary movements associated with Huntington's disease.
• To investigate the relationship between plasma sodium valproate concentrations and motor symptom improvement.
• To assess the impact of arousal levels on the measurement of involuntary movements.

Main Methods:

• A clinical assessment was performed on three patients diagnosed with Huntington's disease.
• Sodium valproate was administered, and plasma levels were monitored.
• Objective ultrasound methods were employed to quantify involuntary movements.
• Standardized arousal protocols were implemented during assessments.

Main Results:

• Sodium valproate administration did not lead to a reduction in involuntary movements.
• Observed plasma levels of sodium valproate ranged from 47.0 to 140.8 microgram/ml (mean 104.7).
• No significant correlation was found between plasma drug levels and motor symptom improvement.

Conclusions:

• Sodium valproate, despite achieving therapeutic plasma concentrations, showed no benefit in managing chorea in Huntington's disease.
• The study highlights the critical role of consistent patient arousal in accurately assessing involuntary movement disorders.
• Further research into GABAergic agents or alternative therapeutic strategies for Huntington's disease is warranted.